LifeStance Health Group (NASDAQ:LFST) Stock Rating Upgraded by The Goldman Sachs Group

The Goldman Sachs Group upgraded shares of LifeStance Health Group (NASDAQ:LFST) from a neutral rating to a buy rating in a report released on Monday, MarketBeat reports. The Goldman Sachs Group currently has $10.00 price target on the stock.

Separately, Barclays lifted their price objective on LifeStance Health Group from $6.00 to $7.00 and gave the stock an “underweight” rating in a research report on Monday, November 11th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, LifeStance Health Group has a consensus rating of “Hold” and an average price target of $8.70.

LifeStance Health Group Stock Performance

NASDAQ:LFST opened at $7.09 on Monday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.32 and a current ratio of 1.32. LifeStance Health Group has a fifty-two week low of $4.64 and a fifty-two week high of $9.20. The company has a 50 day simple moving average of $7.20 and a two-hundred day simple moving average of $6.37. The company has a market capitalization of $2.71 billion, a PE ratio of -27.27 and a beta of 1.28.

LifeStance Health Group (NASDAQ:LFST) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.05. LifeStance Health Group had a negative net margin of 7.90% and a negative return on equity of 6.66%. The company had revenue of $312.70 million for the quarter, compared to analyst estimates of $302.25 million. During the same period in the prior year, the firm posted ($0.17) EPS. The company’s quarterly revenue was up 18.9% on a year-over-year basis. Research analysts anticipate that LifeStance Health Group will post -0.2 earnings per share for the current year.

Insider Activity at LifeStance Health Group

In related news, Director Robert Bessler sold 75,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $7.54, for a total transaction of $565,500.00. Following the transaction, the director now directly owns 1,424,447 shares of the company’s stock, valued at approximately $10,740,330.38. This represents a 5.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On LifeStance Health Group

Hedge funds and other institutional investors have recently modified their holdings of the company. CIBC Asset Management Inc acquired a new stake in shares of LifeStance Health Group in the 2nd quarter worth about $53,000. Algert Global LLC bought a new stake in LifeStance Health Group during the 2nd quarter worth approximately $57,000. Victory Capital Management Inc. increased its holdings in LifeStance Health Group by 27.0% during the 2nd quarter. Victory Capital Management Inc. now owns 14,407 shares of the company’s stock worth $71,000 after purchasing an additional 3,063 shares in the last quarter. Park Edge Advisors LLC purchased a new stake in shares of LifeStance Health Group in the third quarter worth approximately $73,000. Finally, Townsquare Capital LLC bought a new position in shares of LifeStance Health Group in the third quarter valued at approximately $73,000. Institutional investors own 85.50% of the company’s stock.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.